구독하기
연구 모델
서비스
전임상 효능 평가
Resource
huHSC-NKG-hIL15 Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
huHSC-NKG-hIL15 Mouse
제품명
huHSC-NKG-hIL15 Mouse
제품 ID
C001526
품종 계통
huCD34+HSC-NOD.Cg-PrkdcscidIl2rgem1Il15em1(hIL15)/Cya
Backgroud
NKG
상태
이 마우스 계통을 논문에서 사용할 경우, “huHSC-NKG-hIL15 Mouse (카탈로그 번호 C001526)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
Immunodeficient Mice
Humanized Immune System Models
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
Immunodeficient Mice
Humanized Immune System Models
기본 정보
검증 데이터
관련 자료
기본 정보
유전자 별칭
gc, p64, [g]c, CD132, gamma(c), IL-15
염색체
Chr X, Chr 4
MGI ID
Datasheet
품종 계통 설명
NKG mice (Catalog Number: C001316) are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, has reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues.
Interleukin-15 (IL-15) is a cytokine that regulates the activation and proliferation of T cells and natural killer (NK) cells. It also plays a role in balancing the number of CD8+ memory cells alongside IL-2. Research indicates that IL-15 is essential for the differentiation, function, and survival of NK cells. Providing sufficient human IL-15 can help stabilize the function of human NK cells within a mouse model [1-2]. The NKG-hIL15 mice (Catalog Number: C001513) are constructed by knocking in the human IL15 gene from the NKG mice. Compared to NKG mice, NKG-hIL15 mice significantly enhance the reconstitution proportion of human NK cells after HSC or PBMC transplantation. These mice can be utilized for the development of immunotherapies targeting NK cells and drug evaluation.
The huHSC-NKG-hIL15 mouse refers to an immune system humanized mouse model constructed by transplanting human hematopoietic stem cells (HSC) into NKG-hIL15 mice after sub-lethal dose irradiation. This model can reconstitute various immune cells, has a long lifespan, and is particularly effective in rebuilding human NK cells, which can aid in the development of NK cell-related tumor immunotherapies.
Reference
Katano I, Nishime C, Ito R, Kamisako T, Mizusawa T, Ka Y, Ogura T, Suemizu H, Kawakami Y, Ito M, Takahashi T. Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse. Sci Rep. 2017 Dec 8;7(1):17230.
Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, Corcuff E, Mortier E, Jacques Y, Spits H, Di Santo JP. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med. 2009 Jan 16;206(1):25-34.
변형 전략
Typically, 4 to 5-week-old female NKG-hIL15 mice are selected and after irradiation, they receive a tail vein injection of human CD34+ hematopoietic stem cells (HSC).
응용 분야
Research on the human immune system, haematopoietic system;
Human-derived cell line xenograft (CDX) and patient-derived xenograft (PDX);
NK cell development mechanism studies, NK cell-related tumor immunotherapy development, and antibody-dependent NK cell-mediated toxicity (ADCC) studies.
검증 데이터
1. Expression of the human IL15 protein
Compared to NKG mice, NKG-hIL15 mice exhibit significant expression of the human IL15 protein.
Figure 1. ELISA analysis of the human IL15 protein in the 5-week-old female homozygous NKG-hIL15 mice and NKG mice.
2. huHSC-NKG-hIL15 mice for human immune system reconstitution
（1）Survival and growth curves
After myeloablation by irradiation, NKG-hIL15 mice were transplanted with 0.05M human CD34+ hematopoietic stem cells (huHSC) via tail vein injection to construct the huHSC-NKG-hIL15 model. The results demonstrate that huHSC-NKG-hIL15 mice can maintain normal growth, with body weight gradually increasing. These mice maintain a survival rate of approximately 78% at 225 days post engraftment.
Figure 2. Survival status of 4-week-old female huHSC-NKG-hIL15 mice.
（2）Proportion of human leukocytes reconstructed
The results indicate that human leukocytes in the peripheral blood of huHSC-NKG-hIL15 mice rapidly reconstitute by the 3rd-week post engraftment*.
Figure 3. Variation of the human CD45+ leukocytes in the peripheral blood of huHSC-NKG-hIL15 mice.
*The actual efficacy of human immune system reconstitution may vary based on donors and experimental conditions.
*The actual efficacy of human immune system reconstitution may vary based on donors and experimental conditions.
（3）Human T and B cell reconstitution
The results indicate that human T cells in huHSC-NKG-hIL15 mice begin to reconstitute by the 11th week and gradually increase in proportion. By the 27th week, the proportion of human T cells remains around 25%. Human B cells, on the other hand, fluctuate and gradually stabilize after the 3rd week, reaching stability around the 17th week.
Figure 4. Reconstruction effects of human T cells and B cells in huHSC-NKG-hIL15 mice.
（4）Reconstitution of human NK cells
The results indicate that human NK cells rapidly reconstitute between the 3rd and 5th weeks, followed by a subsequent decline in proportion. From the 13th week onward, there is a fluctuating increase, gradually stabilizing by the 17th week. Even at the 27th week, approximately 20% of NK cells can be maintained. Additionally, during the reconstruction process, NKG-hIL15 mice harbor NK cells at different developmental stages*. Notably, successful reconstruction of mature NK cells (CD57+) has been achieved.
Figure 4. Reconstruction effects of human NK cells in huHSC-NKG-hIL15.
*NKG2D: expressed during early NK cell development and remains active in mature NK cells; KIR3DL: expressed during mid-to-late NK cell development; CD57: expressed during the final stage of NK cell maturation.
*NKG2D: expressed during early NK cell development and remains active in mature NK cells; KIR3DL: expressed during mid-to-late NK cell development; CD57: expressed during the final stage of NK cell maturation.
관련 자료
1:1 상담
문의 사항이나 도움이 필요하신가요? <br> 아래 양식을 작성해 주시면 Cyagen 팀이 1~2 영업일 이내에 답변드리겠습니다.
관련 제품
모든 관련 제품리소스
출판물
Research
2025-03-27
Essential Regulation of Spermatogonial Stem Cell Fate Decisions and Male Fertility by APBB1 via Interaction with KAT5 and GDF15 in Humans and Mice
Items: 1 to 1 of 1
1
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.